[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360505-105":59,"doc-detail-360505-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","a-cyclin-d1cdk46e2f-dependency-represents-an-acquired-vulnerability-in-cisplatin-resistant-bladder-cancer","A cyclin D1–CDK4/6–E2F dependency represents an acquired vulnerability in cisplatin-resistant bladder cancer","","Cisplatin resistance remains a major barrier to bladder cancer treatment. This study aimed to identify molecular drivers responsible for cisplatin resistance and to evaluate therapeutic targets capable of restoring treatment responsiveness. Integrative transcriptomic analyses compared TCGA cisplatin non-responders versus responders and used a cisplatin-resistant bladder cancer cell model to detect dysregulated pathways. Functional experiments, including knockdown and multiple cell and molecular assays, characterized pathway changes and therapeutic implications.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-cyclin-d1cdk46e2f-dependency-represents-an-acquired-vulnerability-in-cisplatin-resistant-bladder-cancer/360505/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-cyclin-d1cdk46e2f-dependency-represents-an-acquired-vulnerability-in-cisplatin-resistant-bladder-cancer/360505.png","ImageObject",300,407,{"name":92,"@type":93},"Mabel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in bladder cancer treatment?","Question",{"text":112,"@type":113},"The study addresses cisplatin resistance, a major obstacle that limits effective treatment outcomes for bladder cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the researchers identify molecular drivers of cisplatin resistance?",{"text":117,"@type":113},"They used integrative transcriptomic analyses of TCGA data and a cisplatin-resistant bladder cancer cell model, followed by functional validation using knockdown and multiple experimental assays.",{"name":119,"@type":110,"acceptedAnswer":120},"What key finding links Cyclin D1/CDK4/6 to cisplatin-resistant bladder cancer?",{"text":121,"@type":113},"Cisplatin-resistant samples and cells showed upregulation of CCND1 and enrichment of E2F target genes, and Cyclin D1 silencing restored cisplatin sensitivity.",{"name":123,"@type":110,"acceptedAnswer":124},"Why is abemaciclib relevant for combination therapy with cisplatin?",{"text":125,"@type":113},"Abemaciclib inhibited proliferation of cisplatin-resistant cells, reduced RB phosphorylation, affected cell-cycle and repair regulators, and synergistically suppressed tumor growth when combined with cisplatin.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},360505,1790510675,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":36,"preview_page_count":19,"preview_urls":149},7971474920318,"https://ap-avatar.wpscdn.com/avatar/74000ee537e6b0ca360?x-image-process=image/resize,m_fixed,w_180,h_180&k=1788430171632181674","Hsieh et al. Biology Direct (2026) 21:99 [https://doi.org/10.1186/s13062-026-00812-5](https://doi.org/10.1186/s13062-026-00812-5)  \nBiology Direct  \nRESEARCH Open Access  \nA cyclin D1–CDK4/6–E2F dependency represents an acquired vulnerability in cisplatin-resistant bladder cancer  \nTsung-Han Hsieh 1†, Han-Pin Kuo2,3†, Chun-Hsu Pan4, Yu-Chen Lin5, Bo-Jyun Lin5, Mei-Chuan Chen4,6* and Chun-Han Chen5,7*  \nAbstract  \nBackground Cisplatin resistance remains a major obstacle in the treatment of bladder cancer (BC) . This study aimed to define molecular drivers of cisplatin resistance and to assess potential therapeutic targets that may help restore treatment responsiveness.  \nMethods Integrative transcriptomic analyses were performed using The Cancer Genome Atlas (TCGA) cohort to compare cisplatin non-responders with responders, alongside a cisplatin-resistant BC cell model to identify dysregulated pathways. Functional studies, including siRNA-mediated knockdown, SRB assay, flow cytometry, western blotting, and microarray-based transcriptomics, sphere formation assay, and clonogenic assay, were used to characterize the dysregulated pathways.  \nResults Both cisplatin non-responders inTCGA dataset and resistant BC cells exhibited upregulation of CCND1 and enrichment of E2F target genes. Silencing Cyclin D1 restored cisplatin sensitivity in resistant BC cells. Abemaciclib, a CDK4/6 inhibitor, selectively inhibited proliferation of cisplatin-resistant BC cells, reduced RB phosphorylation, induced sub-G1 accumulation, and suppressed expression of key regulators of cell-cycle progression and homologous recombination repair. Combined treatment with abemaciclib and cisplatin synergistically suppressed the proliferation of cisplatin-resistant BC cells in vitro and produced significantly greater tumor growth inhibition in an RT112 xenograft model in vivo. Furthermore, Abemaciclib reduced sphere-forming capability and enhanced the anti-clonogenic effect of cisplatin in cisplatin-resistant BC cells.  \nConclusion These findings identify a Cyclin D1/CDK4/6–E2F signaling dependency as a characteristic feature of the cisplatin-resistant state in BC. Targeting this acquired vulnerability provides a mechanistic rationale for combination strategies to enhance cisplatin responsiveness for refractory BC.  \nKeywords Bladder cancer, Cisplatin resistance, Cyclin D1, CDK4/6, Abemaciclib  \n†Tsung-Han Hsieh and Han-Pin Kuo contributed equally to this work.  \n*Correspondence:  \nMei-Chuan Chen [mcchen1250@tmu.edu.tw](mcchen1250@tmu.edu.tw)[ ](mcchen1250@tmu.edu.tw)Chun-Han Chen [brianchc@tmu.edu.tw](brianchc@tmu.edu.tw)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nHsieh et al. Biology Direct (2026) 21:99  \nIntroduction  \nBladder cancer (BC) is the second most common genitourinary malignancy worldwide, with a","cbCaijK5nmYah6DS","https://ap.wps.com/l/cbCaijK5nmYah6DS","pdf",7444260,16,"English","# Abstract\n# Introduction\n## Background and unmet clinical need\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What problem does the study address in bladder cancer treatment?\",\"answer\":\"The study addresses cisplatin resistance, a major obstacle that limits effective treatment outcomes for bladder cancer.\"},{\"question\":\"How did the researchers identify molecular drivers of cisplatin resistance?\",\"answer\":\"They used integrative transcriptomic analyses of TCGA data and a cisplatin-resistant bladder cancer cell model, followed by functional validation using knockdown and multiple experimental assays.\"},{\"question\":\"What key finding links Cyclin D1/CDK4/6 to cisplatin-resistant bladder cancer?\",\"answer\":\"Cisplatin-resistant samples and cells showed upregulation of CCND1 and enrichment of E2F target genes, and Cyclin D1 silencing restored cisplatin sensitivity.\"},{\"question\":\"Why is abemaciclib relevant for combination therapy with cisplatin?\",\"answer\":\"Abemaciclib inhibited proliferation of cisplatin-resistant cells, reduced RB phosphorylation, affected cell-cycle and repair regulators, and synergistically suppressed tumor growth when combined with cisplatin.\"}]","A cyclin D1–CDK4/6–E2F dependency represents an acquired vulnerability in cisplatin-resistant bladder cancer | PDF",1790140310,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f355dcf071159c7e5e41f10392a863c2.webp",983,1310,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49c4508add73e2af2de06814204900ed.webp",982,1309,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91bbe17e6ad8fd3cd8563b444b46f27f.webp",981,1308,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/677abbc014d7d904a4d4001153ae3c4f.webp",980,1306]